Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Summary

This is a first-in-human, open label, multicenter, dose escalation study of RXDX-106 in patients with locally advanced or metastatic solid tumors, who have no available therapy likely to convey clinical benefit. This study will examine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of RXDX 106.

Timeline

Start

2018-02-15

Primary completion

2018-06-05

Completion

2018-06-05

Outcome

Outcome not reported

Stopped: “Sponsor's decision”

Drugs

Indications

No indication recorded.